The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Luxiq Foam, 0.12 percent, from Norvium Bioscience, LLC (Norvium), it said.

Alembic Pharma claims to have a total of 213 ANDA approvals (185 final approvals and 28 provisional approvals) from the USFDA.

Performance in the first quarter of the 2025 financial year

The pharmaceutical company’s consolidated net profit rose 11.7 percent to Rs 134.7 crore in Q1FY25 as compared to Rs 121 crore in Q1FY24. Operating income increased 5.1 percent year-on-year to Rs 1,561.7 crore in Q1FY25.

Earnings before interest, taxes, depreciation and amortization (EBITDA) increased 14 percent year-on-year to Rs 239 million, while EBITDA margin was 15.3 percent during the same period.

Alembic Pharmaceuticals Limited is one of the leading pharmaceutical research and development companies, founded in 1907. Headquartered in Vadodara, Gujarat, Alembic is known for its vertically integrated operations and state-of-the-art research and manufacturing facilities approved by the regulatory authorities of several developed countries including USFDA. The company has a strong marketing team of over 5,000 professionals.

Alembic Pharmaceuticals has a market capitalization of Rs 21,906.96 crore as per Bombay Stock Exchange (BSE). The stock’s 52-week high is Rs 1,285.60 while the 52-week low is Rs 707.50 per share.

At 11:07 am, shares of Alembic Pharma were trading 1.27 percent higher at Rs 1,114.50 per share. In comparison, the BSE Sensex was trading 0.64 percent higher at Rs 81,608.95.

First published: 26 August 2024 | 11:18 am IS